Literature DB >> 30347300

Impact of Multifocality and Molecular Markers on Survival of Glioblastoma.

Yahya Ahmadipour1, Ramazan Jabbarli2, Oliver Gembruch2, Daniela Pierscianek2, Marvin Darkwah Oppong2, Philipp Dammann2, Karsten Wrede2, Neriman Özkan2, Oliver Müller2, Ulrich Sure2, Nicolai El Hindy3.   

Abstract

OBJECTIVE: Several parameters like extent of resection and MGMT promotor methylation in glioblastoma (GBM) are known to influence survival. Other elements like multifocality and proliferation indices are not commonly used. The aim of the present study was to analyze routinely and not routinely assessed prognostic markers for survival of patients suffering from GBM in a single center.
METHODS: Adult cases with GBM operated at our institution were included in this survey. The association of age, Karnofsky performance status (KPS), MGMT promotor methylation, Ki67 proliferation index, IDH1/2 mutational status, and multifocality on overall survival (OS) was analyzed in univariate and multivariate cox regression models.
RESULTS: We analyzed 565 patients with a mean age of 62.2 (18-84) years. Median OS was 12.5 months. MGMT promoter methylation and IDH 1/2 mutation were associated with significant better OS (P < 0.01). In 48 cases (8.5%), the tumor was localized in both hemispheres, which was associated with a significant worse OS than tumor infiltration of 1 hemisphere (P = 0.039). Mean Ki67 proliferation index increased to 18% when both hemispheres were infiltrated. Multivariate analysis for OS revealed IDH 1/2 wildtype (adjusted odds ratio [aOR] 4.3), higher age (aOR 4.2), unmethylated MGMT promotor (aOR 3.5), preoperative KPS score <70 (aOR 1.9), and multifocality (aOR 2.1) as independent parameters for worse survival.
CONCLUSIONS: This study confirms well-known parameters like MGMT promoter methylation, IDH 1/2 mutational status, KPS, and age as independent prognostic factors for survival and reveals multifocality as further independent prognostic marker for survival. The dismal prognosis of multifocal involvement is associated with an increasing Ki67 proliferation index.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glioblastoma; Molecular markers; Multifocality; Overall survival

Mesh:

Substances:

Year:  2018        PMID: 30347300     DOI: 10.1016/j.wneu.2018.10.075

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  11 in total

1.  Influence of wide opening of the lateral ventricle on survival for supratentorial glioblastoma patients with radiotherapy and concomitant temozolomide-based chemotherapy.

Authors:  Taiichi Saito; Yoshihiro Muragaki; Takashi Maruyama; Takashi Komori; Masayuki Nitta; Shunsuke Tsuzuki; Atsushi Fukui; Takakazu Kawamata
Journal:  Neurosurg Rev       Date:  2019-11-08       Impact factor: 3.042

2.  Ventricular entry during surgical resection is associated with intracranial leptomeningeal dissemination in glioblastoma patients.

Authors:  Francesca Battista; Giovanni Muscas; Francesca Dinoi; Davide Gadda; Alessandro Della Puppa
Journal:  J Neurooncol       Date:  2022-10-23       Impact factor: 4.506

3.  Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.

Authors:  Sohil H Patel; Prem P Batchala; Thomas J Eluvathingal Muttikkal; Sergio S Ferrante; James T Patrie; Camilo E Fadul; David Schiff; M Beatriz Lopes; Rajan Jain
Journal:  J Neurooncol       Date:  2021-03-04       Impact factor: 4.130

4.  On the Prognosis of Multifocal Glioblastoma: An Evaluation Incorporating Volumetric MRI.

Authors:  Johannes Kasper; Nicole Hilbert; Tim Wende; Michael Karl Fehrenbach; Florian Wilhelmy; Katja Jähne; Clara Frydrychowicz; Gordian Hamerla; Jürgen Meixensberger; Felix Arlt
Journal:  Curr Oncol       Date:  2021-04-07       Impact factor: 3.677

5.  The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma.

Authors:  Chao Gan; Daniela Pierscianek; Nicolai El Hindy; Yahya Ahmadipour; Kathy Keyvani; Ulrich Sure; Yuan Zhu
Journal:  BMC Cancer       Date:  2020-07-17       Impact factor: 4.430

6.  Diagnostic performance of clinical properties and conventional magnetic resonance imaging for determining the IDH1 mutation status in glioblastoma: a retrospective study.

Authors:  Qun Wang; Jiashu Zhang; Fangye Li; Xinghua Xu; Bainan Xu
Journal:  PeerJ       Date:  2019-06-21       Impact factor: 2.984

7.  Decreased CD8+ Lymphocytic Infiltration in Multifocal and Multicentric Glioblastomas.

Authors:  Run Wang; Yifu Song; Tianhao Hu; Xiaoliang Wang; Yang Jiang; Di Zhang; Juanhan Yu; Sheng Han; Liang Kan
Journal:  Front Oncol       Date:  2021-09-27       Impact factor: 6.244

8.  Reduced Serum sRANKL and sTREM2 Levels in High-Grade Gliomas: Association with Prognosis.

Authors:  Mustafa Efendioğlu; Elif Şanli; Ceren Türkoğlu; Naci Balak
Journal:  Noro Psikiyatr Ars       Date:  2021-06-03       Impact factor: 1.339

9.  Comorbid Medical Conditions as Predictors of Overall Survival in Glioblastoma Patients.

Authors:  Matthew T Carr; Camille J Hochheimer; Andrew K Rock; Alper Dincer; Lakshmi Ravindra; Fan Lily Zhang; Charles F Opalak; Nora Poulos; Adam P Sima; William C Broaddus
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

10.  Red blood cell distribution width to platelet ratio substantiates preoperative survival prediction in patients with newly-diagnosed glioblastoma.

Authors:  Matthias Schneider; Niklas Schäfer; Stefanos Apallas; Anna-Laura Potthoff; Christian Bode; Erdem Güresir; Muriel Heimann; Felix Lehmann; Elisa Scharnböck; Christina Schaub; Hartmut Vatter; Ulrich Herrlinger; Patrick Schuss
Journal:  J Neurooncol       Date:  2021-08-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.